Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan
1 other identifier
observational
28
1 country
2
Brief Summary
This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2019
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 5, 2018
CompletedFirst Posted
Study publicly available on registry
October 9, 2018
CompletedStudy Start
First participant enrolled
February 22, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 23, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 23, 2019
CompletedAugust 28, 2019
August 1, 2019
4 months
October 5, 2018
August 23, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Medication usage
From start point for 2.5 months
Treatment's duration
From start point for 2.5 months
Secondary Outcomes (4)
Cost of medication used
From start point for 2.5 months
Costs of adverse event management
From start point for 2.5 months
Frequency of health resource usage
From start point for 2.5 months
Cost of health resource usage
From start point for 2.5 months
Eligibility Criteria
Hospital chart review study
You may qualify if:
- Patients with confirmed diagnosis of clear-cell renal cell carcinoma
- Patients with evidence of metastatic disease
- Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib
- Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease
You may not qualify if:
- Patients enrolled in any clinical trial involving anti-cancer therapy
- Pregnant woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ipsenlead
Study Sites (2)
National Taiwan University Hospital
Taipei, 100, Taiwan
Taipei Veterans General Hospital
Taipei, 112, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ipsen Medical Director
Ipsen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 5, 2018
First Posted
October 9, 2018
Study Start
February 22, 2019
Primary Completion
June 23, 2019
Study Completion
June 23, 2019
Last Updated
August 28, 2019
Record last verified: 2019-08